[1] PATOCKA J, NEPOVIMOVA E, WU W, et al.Digoxin: pharmacology and toxicology-a review[J]. Environ Toxicol Pharmacol, 2020, 79(1): 103400. [2] SCARPIS E, CAUTERO P, TULLIO A, et al.Are adverse events related to the completeness of clinical records? Results from a retrospective records review using the global trigger tool[J]. International Journal for Quality in Health Care, 2023, 35(4): 56. [3] VALKONEN V, HAATAINEN K, SAANO S, et al.Evaluation of global trigger tool as a medication safety tool for adverse drug event detection-a cross-sectional study in a tertiary hospital[J]. European Journal of Clinical Pharmacology, 2023, 79(5): 617-625. [4] ROZICH JD, HARADEN CR, RESAR RK.Adverse drug event trigger tool: a practical methodology for measuring medication related harm[J]. Quality & Safety in Health Care, 2003, 12(3): 194-200. [5] CAI K, XU M.Research and application progress of the global trigger tool in medical adverse event monitoring[J]. Herald of Medicine(医药导报), 2023, 42(4): 584-590. [6] ZHANG X, MENGDAN X, WENGE C, et al.Research on national sentinel alliance for adverse drug reaction surveillance based on CHPS[J]. Chinese Pharmaceutical Affairs(中国药事), 2019, 33(2): 137-142. [7] KONSTANTINOU DM, KARVOUNIS H, GIANNAKOULAS G.Digoxin in heart failure with a reduced ejection fraction: a risk factor or a risk marker?[J]. Cardiology, 2016, 134(3): 311-319. [8] MARCK PV, PIERRE SV.Na/K-ATPase Signaling and cardiac pre/postconditioning with cardiotonic steroids[J]. Int J Mol Sci, 2018, 19(8): 2336. [9] KOMATSU T, MORITA M, MIYAJI F, et al.Population pharmac- okinetics and optimization of the dosing regimen of digoxin in adult patients[J]. J Pharm Health Care Sci, 2015, 1(1): 25. [10] ANDREWS P, ANSEEUW K, KOTECHA D, et al.Diagnosis and practical management of digoxin toxicity: a narrative review and consensus[J]. Eur J Emerg Med, 2023, 30(6): 395-401. [11] RUTBERG H, BORGSTEDT RISBERG M, SJÖDAHL R, et al. Characterisations of adverse events detected in a university hospital: a 4-year study using the global trigger tool method[J]. BMJ Open, 2014, 4(5): e4879. [12] KE X, TAO H.The analysis on the influence factors of medical adverse event reporting system[J]. Medicine and Society(医学与社会), 2012, 25(1): 61-64. [13] BAI H, NIE X, XIA L, et al.Effect evaluation of adverse drug reactions monitoring based on the Chinese hospital pharmacovigilance system[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2022, 19(10): 1136-1139. [14] MORAES SM, FERRARI T CA, BELEIGOLI A.The accuracy of the global trigger tool is higher for the identification of adverse events of greater harm: a diagnostic test study[J]. International Journal for Quality in Health Care, 2023, 34(1): 5. [15] ZHENG M, SHEN A, ZHU W, et al.A study of willingness to use Chinese Hospital Pharmacovigilance System based on structural equation modeling[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2023, 20(7): 772-782. |